540 related articles for article (PubMed ID: 33365294)
1. Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism.
Zin CS; Taufek NH; Bux SH
Front Public Health; 2020; 8():551328. PubMed ID: 33365294
[TBL] [Abstract][Full Text] [Related]
2. Trends in the Cost of Medicines, Consultation Fees and Clinic Visits in Malaysia's Private Primary Healthcare System: Employer Health Insurance Coverage.
Zin CS; Ab Rahman NS; Mohamed Nazar NI; Kurdi A; Godman B
J Multidiscip Healthc; 2023; 16():1683-1697. PubMed ID: 37350986
[TBL] [Abstract][Full Text] [Related]
3. Physician and Patient Adjustment to Reference Pricing for Drugs.
Robinson JC; Whaley C; Brown TT; Dhruva SS
JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
[TBL] [Abstract][Full Text] [Related]
4. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
Robinson JC; Whaley C; Brown TT
JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Thatte U; Hussain S; de Rosas-Valera M; Malik MA
Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
[TBL] [Abstract][Full Text] [Related]
6. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
[TBL] [Abstract][Full Text] [Related]
7. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
[TBL] [Abstract][Full Text] [Related]
8. Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Advanced Imaging Tests.
Robinson JC; Whaley C; Brown TT
Med Care; 2016 Dec; 54(12):1050-1055. PubMed ID: 27479594
[TBL] [Abstract][Full Text] [Related]
9. Association between availability of health service prices and payments for these services.
Whaley C; Schneider Chafen J; Pinkard S; Kellerman G; Bravata D; Kocher R; Sood N
JAMA; 2014 Oct 22-29; 312(16):1670-6. PubMed ID: 25335149
[TBL] [Abstract][Full Text] [Related]
10. Increases in consumer cost sharing redirect patient volumes and reduce hospital prices for orthopedic surgery.
Robinson JC; Brown TT
Health Aff (Millwood); 2013 Aug; 32(8):1392-7. PubMed ID: 23918483
[TBL] [Abstract][Full Text] [Related]
11. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
12. Effect of privatization of the drug distribution system on drug prices in Malaysia.
Babar ZD; Izham MI
Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741
[TBL] [Abstract][Full Text] [Related]
13. Association of Reference Pricing with Drug Selection and Spending.
Robinson JC; Whaley CM; Brown TT
N Engl J Med; 2017 Aug; 377(7):658-665. PubMed ID: 28813219
[TBL] [Abstract][Full Text] [Related]
14. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
15. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
de Jager H; Suleman F
Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
[TBL] [Abstract][Full Text] [Related]
16. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
17. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
18. Insurance coverage and the treatment of mental illness: effect on medication and provider use.
Mulvale G; Hurley J
J Ment Health Policy Econ; 2008 Dec; 11(4):177-99. PubMed ID: 19096092
[TBL] [Abstract][Full Text] [Related]
19. Sales and pricing decisions for HIV self-test kits among local drug shops in Tanzania: a prospective cohort study.
Chiu C; Hunter LA; McCoy SI; Mfaume R; Njau P; Liu JX
BMC Health Serv Res; 2021 May; 21(1):434. PubMed ID: 33957903
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial drug use in primary healthcare clinics: a retrospective evaluation.
Shamsuddin S; Akkawi ME; Zaidi ST; Ming LC; Manan MM
Int J Infect Dis; 2016 Nov; 52():16-22. PubMed ID: 27639454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
